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Shortages of opioid analgesics are increasingly common, interfere with patient care and
increase healthcare cost. This study characterized the incidence of shortages of opioid anal-
gesics in the period 2015–2019 and evaluated potential predictors to forecast the risk of
shortages.
Methods
This was an observational retrospective study using the US Food and Drug Administration
(FDA) drug shortages data. All FDA approved opioids were included in the study. Opioid
analgesics were identified using the FDA National Drug Codes (NDC) and classified accord-
ing to the Drug Enforcement Administration (DEA) schedule. We conducted Least Absolute
Shrinkage and Selection Operator logistic regression analysis to assess direction of the
association between risk of shortage and potential predictors. We used multivariable penal-
ized logistic regression analysis to model predictors of shortages. We split the dataset into
training and validation sets to evaluate the performance of the model.
Findings
The FDA approved 8,207 unique NDCs for opioid analgesics; 3,017 (36.8%) were in the
market as of April 30, 2019 and 91(3.0%) of them were listed as in shortage by the FDA. All
NDCs in shortage were schedule II opioids; 86 (94.5%) were injectable and 84 (92.3%)
generics. There were 418 companies with at least one opioid NDC listed by the FDA. Three
companies accounted for more than 4 in 5 of the schedule II active injectable opioids. For
each unit increase in the number of prior instances of shortages of a company, the likelihood
of an NDC shortage for that company increased by 3.4%. For each unit increase in number
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of NDCs marketed by a company, the odds of an NDC shortage for that company decreased
by 1%.
Conclusions
In the period 2015–2019, shortages of opioid analgesics disproportionally impacted sched-
ule II and injectable opioids. The risk of shortage of opioid analgesics significantly increased
with the incidence of previous instances of shortages of a manufacturing company and
decreased with the number of NDCs marketed by a company. The characteristics of the
manufacturing company, rather than the number of companies, might be the missing piece
to the complex puzzle of drug shortages in the US.
Introduction
The number of drug shortages has risen steadily in the United States (US) since 2005 [1, 2].
Drug shortages are a significant ongoing threat to patient safety by increasing patient morbid-
ity and mortality [3–5]. Due to drug shortages, clinicians often have to turn to therapeutic
alternatives, forms or strengths that may be less effective or with which they may not be famil-
iar, increasing the risk of medication errors [6]. Drug shortages may trigger sudden changes in
formularies and clinical decision-support systems that disrupt the continuity of patient care
[5]. In addition, drug shortages increase health care costs associated with changes to more
expensive therapeutic alternatives and drug formulations, tracking inventories, relocating
units left in inventory and stockpiling, and other drug procurement strategies that often follow
the reporting of a shortage. Drug shortages often result in wasteful healthcare spending for
insurers, providers and patients [4, 7].
Shortages of opioid analgesics have become increasingly common, a trend that is projected
to continue [8]. These shortages are related to Drug Enforcement Administration opioid
manufacturing quotas, in response to the opioid-overdose epidemic and manufacturing prob-
lems, including violations in good manufacturing practices [9]. Shortages of opioid analgesics
have the potential to negatively impact the care provided to surgical patients by compromising
pain control after surgery and increasing opioid-related adverse events arising from drug sub-
stitutions [10]. The shortage of opioid analgesics is not expected to be resolved in the near
future. Hence, healthcare settings will need to implement prevention and mitigation strategies.
Preventing and mitigating the impact of drug shortages require a thorough understanding of
the pharmaceutical sector, the drug market and market dynamics.
Prior studies assessed overall trends of pharmaceutical shortages in the US for specific drug
classes including antimicrobials, cancer chemotherapy, and cardiovascular and neurologic
drugs [1, 2, 4, 8, 11]. Despite its high prevalence and incidence, little is known about the char-
acteristics of shortages of opioid analgesics. This study characterized and assessed the inci-
dence of shortages of opioid analgesics in the US in the period 2015–2019 and evaluated
potential predictors to forecast the risk of shortages.
Materials and methods
This was an observational retrospective study. Shortage data were collected from the US Food
and Drug Administration (FDA) website [12]. We collected FDA data for the first reported
shortage date during the period 2015–2019. FDA approved opioids data including abbreviated
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new drug applications (ANDAs) and new drug applications (NDAs) were derived from the
electronic version of the “Approved Drug Products with Therapeutic Equivalence Evaluations”
(Orange Book). Opioid analgesics were identified by their national drug codes (NDCs) using
the FDA NDC directory and classified according to the Drug Enforcement Administration
(DEA) schedule [13]. Active ingredient, strength, dosage form, generic and trade names, mar-
ket discontinuation indicator, unit-dose indicator, company identifier, and drug price data
were derived from the IBM Micromedex Red Book (RB) [14]. Opioid shortages data and opi-
oid analgesics information were linked using the NDC to create a unique dataset.
This study used the NDC as the unit of analysis. The NDC is a unique three-segment num-
ber that identifies the manufacturer, the drug product, and package. Study categorical variables
included administration route, active ingredient, and formulation (extended release and
immediate release opioid), form (tablets, capsules, patches, suppositories), manufacturer
name, NDC market discontinuation indicator, unit dose and fixed-dose drug combination
indicators, generic and brand name indicator. Drug administration routes included injectables
(epidural, intramuscular, intrathecal, intravenous), oral (tablets, pills) and other (nasal, rectal,
transdermal). Continuous variables included strength, drug unit and package average whole-
sale price (AWP), and number of manufacturers, ANDAs, NDAs and NDCs by market status
(active and discontinued) and number of manufacturers for any given NDC and for any given
number of active ingredients. The company risk of shortage was defined as the number of
NDCs a company had in shortage prior to a given NDC being in shortage. We hypothesized
that the greater the number of NDCs a company had in shortage, the greater the likelihood
that the company will have a future NDC in shortage.
We used Chi-square two-independent sample test to assess significant differences between
incidence of shortages and categorical variables. We used Wilcoxon non-parametric tests of
medians for non-normally distributed continuous variables. We conducted bivariate logistic
regression analysis to assess association between risk of shortage and potential predictors. In
addition, we conducted Least Absolute Shrinkage and Selection Operator (LASSO) logistic
regression analysis to assess direction of the association between risk of shortage and potential
predictors. Last, we used multivariable penalized logistic regression analysis to model predic-
tors of shortages. Overall, 44 potential predictive variables were assessed in the LASSO regres-
sion analysis including drug administration route, NDCs marketed and discontinued,
extended release and fixed-dose combination drug indicator, generic and unit dose indicator,
DEA schedule, number of companies manufacturing any given active ingredient, strength and
route, number of NDCs marketed by any given company and drug unit and package AWP
price and company risk and combinations of these predictors. Of the potential predictors,
coefficients of 24 variables were not penalized to zero and therefore, remained significant pre-
dictors. Final regression analysis included 4 variables that were independently statistically sig-
nificant predictors of shortages of opioids.
Our penalized logistic regression model followed a bias-reduced Generalized Linear Model
adjustment that uses Firth’s correction to address perfect separation for low incidence observa-
tions. We reported log odds (beta estimates), standard error and odds ratios (exponentiated
beta estimates) with 95% confidence intervals (CI) for predictors of shortages (Fig 1). We used
Kendall’s tau correlation coefficients to assess potential correlation among covariates (Fig 2).
In addition, we assessed multicollinearity in the penalized logistic regression model using the
variance inflation factor (VIF < 5) and correlation matrix of parameter estimates (±1).
Last, we split the dataset into training and validation sets using 70:30 ratio, respectively, to
evaluate the performance of the model. The training data sample was used to fit the model.
Model fit was assessed using Hosmer-Lemeshow (H-L) statistic (H-L > 0.05). The validation
set was used to assess model’s predictive performance using the area under the receiver
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operator characteristic (ROC) curve. We also computed confusion matrix using the cut-off
threshold probability identified by ROC curve to assess classification accuracy of the model.
We used odds ratios and beta estimate coefficient plots to represent penalized logistic
Fig 1. Shortages of opioids: Odds ratios estimates.
https://doi.org/10.1371/journal.pone.0249274.g001
Fig 2. Kendall’s tau correlation coefficients for predictors of shortages.
https://doi.org/10.1371/journal.pone.0249274.g002
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regression model results to visualize direction and strength of association between risk of
shortages and covariates. Analyses were performed using R software (version 3.6.2, R Founda-
tion). A p-value < .05 was considered statistically significant.
Results
Incidence of shortages of FDA approved opioid analgesics
The FDA listed 8,207 unique NDCs for opioid analgesics (Table 1). Overall, 5,726 (69.8%) of
the FDA approved opioids were classiffied by the DEA as schedule II. Of the total (105, 1.3%)
NDCs in shortage at the FDA as of April 2019, 104 (99.0%) were schedule II, 89 (84.8%)
injectable, and 91(86.7%) generics. Overall, 418 companies had at least one opioid NDC listed
by the FDA. Of them, 183 (43.7%) had at least one active opioid NDC as of April 30, 2019 and
16 (3.8%) companies were marketing schedule II injectable opioids. The median (IQR) num-
ber of NDCs per company was 6.0 (2.0, 18.0) for all NDCs, and 5.0 (2.0, 15.5) for active NDCs.
The median number of schedule II injectable NDCs per company was 15.0 (3.5, 36.0); all
schedule II injectable NDCs remained in the market as of April 30, 2019. Likewise, the median
(IQR) number of companies per strength was 2.0 (1.0–4.0) for all NDCs and 1.0 (1.0–3.0) for
active NDCs. The median (IQR) number of companies per schedule II opioid injectable
manufacturing a given strength was 1.0 (1.0–1.0) for all NDCs; the strength remained in the
market as of April 30, 2019.
Shortages of opioids in the US market
Out of 8,207 unique NDC opioids, 3,017 (36.8%) were active as of April 30, 2019 (Table 2). In
the study period, 91(3.0%) of the active NDCs were listed by the FDA as in shortage. All active
NDCs in shortage were schedule II opioids; 86 (94.5%) were injectable and 84 (92.3%) generic
opioids. There were no statistically significant differences in the characteristics of generic opi-
oids in shortage and not in shortage. There were not shortages of fixed-dose combinations or
unit dose opioids. There were significant differences in the incidence of shortages by active
ingredient. The incidence of shortages was higher for morphine (32, 35.2%), hydromorphone
hydrochloride (31, 34.1%), and fentanyl citrate (19, 20.9%). Likewise, the incidence of short-
ages also varied by company. Overall, 91(3.0%) of the active opioid NDCs in shortage were
registered by 7 (3.8%) out of 183 companies with active NDC opioids.
Shortages of schedule II injectable opioids in the US market
There were 1,001 active schedule II NDC injectable opioids in the US market. Of them, 86
(8.6%) were in shortage as of April 30, 2019 (Table 3). Generic drugs represented 96.0%
(n = 961) of the active opioid NDCs and 91.9% (n = 79) of the active NDC shortages. Fentanyl
citrate represented 48.0% (n = 480) of the schedule II injectable opioid NDCs but 22.1%
(n = 19) of the NDC shortages; whereas, hydromorphone hydrochloride represented 23.6%
(n = 236) of the schedule II injectable opioid NDCs but 36.0% (n = 31) of the NDC shortages.
Three companies accounted for 81.4% of the shortages of schedule II injectable opioid NDCs
in the market. Conversely, 770 (76.9%) of the schedule II injectable opioid NDCs were manu-
factured by companies that did not experience any instances of shortages during the study
period.
Predictors of shortages of opioids
The risk of shortage was significantly greater for companies that experienced prior instances of
NDC opioid shortages during the study period (OR 1.034; p< 0.01) (Table 4). For a unit
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Table 1. FDA approved opioid NDCs and shortages, 2015–2019.
NDCs % NDCs FDA Shortages % of NDC % of FDA Shortages p value
NDCs 8,207 105 1.3%
Strengths 877 37 4.2%
Companies 418 11 2.6%
DEA Schedule <0.001
CII 5,726 69.8% 104 1.8% 99.0%
CIII 762 9.3%
CIV 757 9.2% 1 0.1% 1.0%
CV 962 11.7%
Route <0.001
Oral 4,881 59.5% 16 0.3% 15.2%
Injectable 2,289 27.9% 89 3.9% 84.8%
Other 1,037 12.6%
Extended release formulation 944 11.5% 16 1.7% 15.2% 0.292
Fixed-dose drug combination 4,734 57.7%
Generic drugs 6,943 84.6% 91 1.3% 86.7% 0.649
Unit dose 597 7.3% 0.007
Active ingredient <0.001
alfentanil hydrochloride 25 0.3%
buprenorphine 137 1.7%
buprenorphine hydrochloride 67 0.8%
codeine phosphate 1340 16.3%
diphenoxylate hydrochloride 123 1.5%
fentanyl 275 3.4%
fentanyl citrate 979 11.9% 21 2.1% 20.0%
hydrocodone 4 0.0%
hydrocodone bitartrate 1276 15.5%
hydrocodone polistirex 27 0.3%
hydrocodone tannate 2 0.0%
hydromorphone hydrochloride 604 7.4% 31 5.1% 29.5%
meperidine hydrochloride 260 3.2% 1 0.4% 1.0%
methadone hydrochloride 118 1.4% 2 1.7% 1.9%
morphine sulfate 1131 13.8% 43 3.8% 41.0%
morphine sulfate liposome 7 0.1%
opium 24 0.3%
oxycodone 5 0.1%
oxycodone hydrochloride; oxycodone terephthalate 35 0.4%
oxycodone hydrochloride 596 7.3%
pentazocine lactate 13 0.2% 1 7.7% 1.0%
remifentanil hydrochloride 19 0.2% 6 31.6% 5.7%
sufentanil citrate 93 1.1%
tramadol hydrochloride 248 3.0%
All other 799 9.7%
Company (Top 10) <0.001
Teva Pharmaceuticals USA 351 4.3% 3 0.9% 2.9%
Hospira, Inc. 231 2.8% 37 16.0% 35.2%
Specgx, LLC 154 1.9%
Par Pharmaceutical 146 1.8% 5 3.4% 4.8%
(Continued)
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increase in the number of prior instances of shortages of a given company, the likelihood of an
NDC shortage increases by 3.4% for that company. In addition, the greater was the number of
NDCs marketed by a company, the lower was the risk of shortages for that company (OR 0.99;
p< 0.001). More specifically, for a unit increase in number of NDCs marketed by a company,
the odds of an NDC shortage decreases by 1%. Compared to brands, the risk of shortage was
greater for generic drugs, although not statistically significant. The number of companies mar-
keting a given strength was also positively associated, but not statistically significant, with the
risk of shortages. The H-L goodness of fit test p = 0.95 and McFadden pseudo R2 of 0.46 evi-
denced a good model fit. In addition, the accuracy of the model was evidenced with an area
under curve (AUC) of 0.918 (0.8868–0.9491). For a ROC probability of 28.0% or greater, our
model would accurately predict the likelihood of an NDC opioid to be listed in shortage by the
FDA 87.0% of the time. The model would also accurately predict the likelihood of an NDC not
to be in shortage. Lastly, the accuracy of the model was also confirmed using the validation set
(S1 Table).
Discussion
This is the first study to comprehensively characterize the market of opioid analgesics and to
identify predictors of shortages. We found that two thirds of the opioid NDCs listed by the
FDA were discontinued from the market. Shortages disproportionally impacted schedule II
and injectable opioids. A few companies and active ingredients accumulated a disproportion-
ately large amount of shortages of opioid analgesics. Three companies accounted for more
than 4 in 5 of the schedule II active injectable opioids. The market of schedule II injectable opi-
oids is highly concentrated and filled with off patent products. Relatively low prices of opioid
analgesics reduced manufacturers’ incentives to remain in the market. In addition, few compa-
nies have the capacity to produce sterile injectable products [15, 16]. Injectable products are
costlier than oral medications, have less clinically interchangeable alternatives and potentially
greater impact on patient care [17, 18].
Table 1. (Continued)
NDCs % NDCs FDA Shortages % of NDC % of FDA Shortages p value
Apotex Corp. 150 1.8%
Amneal Pharmaceuticals Inc. 124 1.5%
Mylan Pharmaceuticals Inc. 98 1.2% 9 9.2% 8.6%
Hikma Pharmaceuticals Inc. 92 1.1% 12 13.0% 11.4%
Fresenius Kabi USA, LLC 55 0.7% 23 41.8% 21.9%
Akorn, Inc. 60 0.7% 9 15.0% 8.6%
All other companies 6,365 77.6%
AWP unit price median(IQR) 0.6 (0.2, 3.3) 2.9 (1.2, 4.3) <0.001
AWP package price median (IQR) 62.5 (22.9, 239.7) 82.7 (30.7, 170.0) 0.05
Missing 481 5.9%
Companies per strength (median(IQR) 2.0 (1.0, 4.0) 8.0 (3.0, 13.0) <0.001
NDCs per company (median(IQR)) 6.0 (2.0, 18.0) 42.0 (11.0, 54.5) 0.005
Injectable included injection, epidural, intramuscular, intrathecal, intravenous. Other administration routes included buccal mucosa, nasal, oromuscular, rectal,
subcutaneous, transdermal. Other active ingredient included benzohydrocodone, butarphanol tartrate, codeine, dezocine, difenoxin hydrochloride, dihydrocodeine
bitartrate, levomethadyl acetate hydrochloride, levorphanol tartrate, nalbuphine hydrochloride, terephthalate, oxymorphone hydrochloride, paregoric, pentazocine
hydrochloride, propoxyphene hydrochloride, propoxyphene napsylate, tapentadol hydrochloride.
https://doi.org/10.1371/journal.pone.0249274.t001
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Table 2. Opioid NDCs marketed and shortages, 2015–2019.
NDCs % NDC Marketed % NDCs p value FDA Shortages % NDC % FDA Shortages p value
NDCs 3,017 36.8% 91 3.0% <0.001
Strengths 524 59.7% 30 5.7%
Companies 183 43.8% 9 4.9%
DEA Schedule <0.001 <0.001
CII 2,519 83.5% 44.0% 91 3.6% 100.0%
CIII 234 7.8% 30.7%
CIV 171 5.7% 22.6%
CV 93 3.1% 9.7%
Route <0.001 <0.001
Oral 1,301 43.1% 26.7% 5 0.4% 5.5%
Injectable 1,030 34.1% 45.0% 86 8.3% 94.5%
Other 686 22.7% 66.2%
Extended release formulation 495 16.4% 52.4% <0.001 5 1.0% 5.5% 0.007
Fixed-dose drug combination 1,155 38.3% 31.8% <0.001
Generic drugs 2,690 89.2% 38.7% <0.001 84 3.1% 92.3% 0.418
Unit dose 270 8.9% 45.2% <0.001 0.004
Active ingredient <0.001 <0.001
alfentanil hydrochloride 11 0.4% 44.0%
buprenorphine 121 4.0% 88.3%
buprenorphine hydrochloride 48 1.6% 71.6%
codeine phosphate 144 4.8% 10.7%
diphenoxylate hydrochloride 20 0.7% 16.3%
fentanyl 196 6.5% 71.3%
fentanyl citrate 563 18.7% 57.5% 19 3.4% 20.9%
hydrocodone bitartrate 417 13.8% 32.7%
hydrocodone polistirex 12 0.4% 44.4%
hydromorphone hydrochloride 314 10.4% 52.0% 31 9.9% 34.1%
meperidine hydrochloride 73 2.4% 28.1% 1 1.4% 1.1%
methadone hydrochloride 77 2.6% 65.3% 2 2.6% 2.2%
morphine sulfate 390 12.9% 34.5% 32 8.2% 35.2%
opium 7 0.2% 29.2%
oxycodone 5 0.2% 100.0%
oxycodone hydrochloride 283 9.4% 47.5%
remifentanil hydrochloride 15 0.5% 78.9% 6 40.0% 6.6%
sufentanil citrate 42 1.4% 45.2%
tramadol hydrochloride 144 4.8% 58.1%
Other 135 4.5% 16.9%
Company (Top 10) <0.001 <0.001
Teva Pharmaceuticals USA 113 3.7% 32.2% 3 3.3% 2.7%
Hospira Inc 125 4.1% 54.1% 35 38.5% 28.0%
Specgx LLC 143 4.7% 92.9%
Par Pharmaceutical 58 1.9% 39.7%
Apotex Corp 93 3.1% 62.0%
Amneal Pharmaceuticals Inc 76 2.5% 61.3%
Mylan Pharmaceuticals Inc 65 2.2% 66.3% 9 9.9% 13.8%
Hikma Pharmaceuticals USA Inc 88 2.9% 95.7% 12 13.2% 13.6%
Fresenius Kabi USA LLC 51 1.7% 92.7% 23 25.3% 45.1%
(Continued)
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We also found that the risk of shortage of an NDC significantly decreases with the total
number of NDCs marketed by the company and increases with the incidence of previous
instances of shortages of the manufacturing company. These findings suggest that the charac-
teristics of the manufacturing company might be the missing piece to the complex puzzle of
Table 2. (Continued)
NDCs % NDC Marketed % NDCs p value FDA Shortages % NDC % FDA Shortages p value
Akorn Inc 48 1.6% 80.0% 8 8.8% 16.7%
All other companies 1882 62.4% 29.6%
AWP unit price median (IQR) 1.5 (0.4,11.7) <0.001 2.7 (1.2,3.6) 0.106
AWP package price median (IQR) 106.4 (32.0,513.1) <0.001 75.7 (30.2,118.6) 0.003
Missing 426 14.1% 88.6%
Companies per strength (median(IQR) 1.0 (1.0, 3.0) 3.0 (2.0,4.0) <0.001
NDCs per company (median(IQR)) 5.0 (2.0,15.5) 22.0 (7.0,38.1) 0.023
Company risk (median (IQR)) 7.0 (3.0, 11.0) <0.001
https://doi.org/10.1371/journal.pone.0249274.t002
Table 3. DEA schedule CII injectable opioid NDCs marketed and shortages, 2015–2019.
NDCs % CII injectable NDC Marketed FDA Shortages % FDA Shortages % NDCs p value
NDCs 1,001 86 8.6% <0.001
Strengths 213 25 11.7%
Companies 16 8 50.0%
Fixed-dose drug combinations 371 37.1%
Generic drugs 961 96.0% 79 91.9% 8.2% 0.078
Unit dose 1 0.1%
Active ingredient <0.001
alfentanil hydrochloride 11 1.1%
fentanyl 5 0.5%
fentanyl citrate 480 48.0% 19 22.1% 4.0%
hydromorphone hydrochloride 236 23.6% 31 36.0% 13.1%
meperidine hydrochloride 45 4.5% 1 1.2% 2.2%
methadone hydrochloride 8 0.8% 2 2.3% 25.0%
morphine sulfate 175 17.5% 27 31.4% 15.4%
remifentanil hydrochloride 15 1.5% 6 7.0% 40.0%
sufentanil citrate 26 2.6%
All companies with active NDCs in shortage <0.001
Akorn, Inc 21 2.1% 8 9.3% 38.1%
Fresenius Kabi USA, LLC 51 5.1% 23 26.7% 45.1%
Hikma Pharmaceuticals USA Inc 42 4.2% 12 14.0% 28.6%
Hospira, Inc 104 10.4% 35 40.7% 33.7%
Mylan Pharmaceuticals, Inc 7 0.7% 4 4.7% 57.1%
Teva Pharmaceuticals USA 5 0.5% 3 3.5% 60.0%
All Other 770 76.9%
AWP unit price median (IQR) 0.3 (0.2, 0.8) 2.6 (1.0, 3.4) <0.001
AWP package price median (IQR) 27.1 (16.6, 46.9) 63.0 (30.0, 106.9) <0.001
Missing 89 8.9%
Companies per strength (median(IQR) 1.0 (1.0, 1.0) 3.0 (2.0, 3.0) <0.001
NDCs per company (median(IQR)) 15.0 (3.5, 36.0) 18.0 (6.5, 37.2) 0.495
Company risk (median (IQR)) 3.0 (0.0, 10.0) 7.5 (2.8, 11.5) 0.183
https://doi.org/10.1371/journal.pone.0249274.t003
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the drug shortages in the US market. Companies manufacturing a greater amount of opioid
NDCs may have more resources and the know-how providing the company with a competitive
advantage. On the other hand, manufacturing companies operate on a just-in-time basis with
very limited capacity to react timely to any problems encountered during the manufacturing
process including disruptions in the supply of raw materials, active pharmaceutical ingredients
(API) and inactive excipients, limited number of API suppliers, staffing shortages, and sterility
testing capacity. In addition, most opioid analgesics have been in the market for more than 30
years and manufacturing companies may have not kept up with maintenance of depreciated
infrastructures and obsolete management systems. Limited manufacturing capacity and
unforeseen production interruptions rapidly lead to drug shortages. The FDA recommenda-
tions to address drug shortages include companies developing redundancy, capability, and
manufacturing capacity [19].
The FDA Drug Shortages Task Force identified lower-priced drugs and sterile injectables as
being potentially more vulnerable to drug shortages [20]. Others suggested that a greater num-
ber of companies marketing a drug would increase competition and reduce the incidence of
shortages. We found that generic opioids and the overall number of companies with active
NDCs for a given strength were positively associated with the risk of shortage–although the
association was not statistically significant. Companies marketing single source drugs may be
able to set higher prices and therefore, have more incentives to prevent market disruptions.
While, each drug company has an intrinsic risk of shortage, there might be an added competi-
tion effect where the risk of shortage among competitor companies increases. These findings
shed light on the debate regarding the role of market competition in the incidence and impact
of shortages of opioid analgesics.
Study findings also have several implications for clinical and pharmacy practice. Shortages
of morphine, hydromorphine, fentanyl, remifentanil commonly used in postoperative pain
management increase the risk of medication errors and perioperative complications [5]. Inpa-
tient administration of therapeutic interchangeable drugs (fentanyl instead of morphine),
enteral opioids, instead of intravenous opioids in patients who can tolerate oral medications,
and dose rounding to reduce drug wastage may also be considered to prevent and mitigate
shortages. Purchasing departments and pharmacy and therapeutic committees across the
nation might consider the likelihood of a dug to be in short supply and the manufacturer spe-
cific risk as part of their purchasing and drug formulary deliberations. Procurement agree-
ments may include contingency clauses, performance requirements, and failure-to-supply
clauses, and low-price clauses and restrictions on limiting downstream price increases to
maintain sustainability of the supply. Procurement and payment policies may be coupled with
Table 4. Multivariable logistic regression model for predicting risk of shortage of opioid analgesics.
Covariates Beta Estimate Standard Error Odds Ratio Odds Ratio 95% Lower Odds Ratio 95% Upper P value
Intercept -2.129 0.644 0.119 0.029 0.397 0.0009530
Generics 0.630 0.463 1.878 0.798 5.990 0.1730577
# Companies per strength 0.271 0.163 1.311 0.947 1.816 0.0966278
# NDCs per company -0.008 0.002 0.992 0.945 0.995 0.0000798
Company risk 0.034 0.012 1.034 1.011 1.283 0.0057170
Hosmer-Lemeshow Statistic p-value:0.95
McFadden pseudo R2: 0.46
Area Under Curve (95% CI):0.918(0.8868–0.9491)
ROC probability cut-off: 0.28
https://doi.org/10.1371/journal.pone.0249274.t004
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a requirement for manufacturers to establish risk management plans to respond efficiently
and effectively to potential shortages.
In addition, drug shortages increase waste and healthcare cost to health plans, providers,
and patients. Excess costs include opioid-related adverse events treatment cost, operation, and
labor cost [4]. Pharmacists devote a significant amount of time to manage drug shortages,
revise treatment protocols and adjust information technology systems and ensure proper clini-
cians’ education regarding alternative medications. Evidence of the financial impacts of drug
shortages remains of paramount importance for purchasers and healthcare providers to make
inform decisions and secure a reliable drug supply. Despite the incidence, persistence and
impacts on healthcare delivery, most hospitals and other healthcare systems have not compre-
hensively quantified the cost of drug shortages [21].
This study has some limitations. Despite the high prevalence and significant impacts of
shortages there is not a harmonized definition of drug shortages. The FDA defines a drug short-
age as a situation in which the total supply of all clinically interchangeable versions of an FDA
regulated drug is inadequate to meet the current or projected demand at the user level [22]. The
FDA reports shortages of products medically necessary to treat or prevent a serious disease or
medical condition for which there is no other appropriate and available substitute. The Ameri-
can Society of Health-System Pharmacists defines pharmaceutical shortages more broadly as a
supply issue that affects how the pharmacy prepares or dispenses a drug product or how patient
care is influenced when prescribers must use alternative products [23]. Furthermore, healthcare
providers across the country may follow their own definitions of drug shortages when products
are on back order, in allocation or not sufficient units remain in inventory to fulfill their target
quantity. In addition, shortage dates vary by data source. We used the first date of an opioid
analgesic was reported in shortage at the FDA website. An active ingredient may have several
administration routes and strengths. Hence, our analysis at the NDC level, rather than the active
ingredient, provides a finer characterization of the drug supply and therapeutic alternatives
available to clinicians. Study variables with 20% or more missing observations were not
included in the analysis (i.e., ANDAs and NDAs by active ingredient). Lastly, regression models
may be subject to bias from unobserved market and drug-related characteristics including the
Drug Enforcement Administration Annual Aggregate Production Quotas for schedule I and II
opioids and manufacturers lack of compliance with Good Manufacturing Practices.
Conclusions
Over eight thousand opioid NDCs were listed by the FDA for marketing in the US. Only one
in three opioid analgesics approved by the FDA were active as of April 30, 2020. Four in five
active opioids in the US market were schedule II opioids and generics. There were significant
differences in the incidence of shortages by active ingredient and manufacturing company.
Three companies accounted for four in five shortages of schedule II injectable opioid NDCs in
the market. For a unit increase in the number of prior instances of shortages of a given com-
pany, the likelihood of an NDC shortage increases by 3.4% for that company. The greater the
number of NDCs marketed by a company, the lower was the risk of shortages for that com-
pany. The overall number of companies marketing an opioid analgesic was not significantly
associated with the risk of shortage.
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